Slo-Niacin.com educates visitors about heart disease, cholesterol management
MAPLE GROVE, Minn. Upsher-Smith on Monday announced the launch of Slo-Niacin.com, an information portal for cholesterol management.
The site educates visitors about heart disease and includes "Cholesterol Basics," a guide to interpreting cholesterol levels and facts about common heart disease risk factors. The website also reviews recommendations on how to optimize cholesterol management, along with tips to leading a healthy lifestyle, including fitness, nutrition and how the integration of a supplement containing nicotinic acid, like the company’s Slo-Niacin brand, can support overall heart health.
"We know how important it is to be informed when it comes to managing overall heart health," stated Tina Fehr, product manager for Slo-Niacin. "The new website gives visitors easy access to credible information about cholesterol management, along with an improved store locator for the ultimate convenience on where to buy Slo-Niacin and how to obtain … coupons."
McNeil’s recall widens as ‘precautionary measure’
FORT WASHINGTON, Pa. McNeil Consumer Healthcare on Thursday issued yet another recall of 21 lots of over-the-counter medicines. This action is a follow-up to a product recall that McNeil originally announced on Jan. 15, which was initiated following consumer complaints of a musty or moldy odor, which has been linked to the presence of trace amounts of a chemical called 2,4,6-tribromoanisole.
Between Jan. 15 and July 8, McNeil has made seven recall announcements, not all because of the TBA chemical, however. The latest lots are being added to the list of recalled products as a precautionary measure after a continuing internal review determined that some packaging materials used in the lots had been shipped and stored on the same type of wooden pallet that was tied to the presence of TBA in earlier recalled lots. All lots involved in the recall were produced before the Jan. 15 recall, after which McNeil stopped accepting shipments of materials from its suppliers on that type of pallet.
McNeil has created a website, McNeilProductRecall.com/index.jhtml, that outlines all products affected from each of the recalls.
FDA issues warning about Que She weight-loss supplement
SILVER SPRING, Md. The Food and Drug Administration on Thursday warned that Que She, marketed as an herbal weight-loss supplement, actually is an adulterated drug product as it contains active pharmaceutical ingredients not listed on the product label that could harm consumers, especially those with cardiovascular conditions.
People who have purchased Que She should stop taking the product immediately and consult a healthcare professional.
Que She, advertised as “Slimming Factor Capsule” and as “an all-natural blend of Chinese herbs,” has been widely distributed on such Internet sites as the Bouncing Bear Botanicals website, and at such retail outlets as Sacred Journey in Lawrence, Kan.
An FDA analysis of Que She found that it contained fenfluramine, a stimulant drug withdrawn from the U.S. market in 1997 after studies demonstrated that it caused serious heart valve damage; propranolol, a prescription beta-blocker drug that can pose a risk to people with bronchial asthma and certain heart conditions; sibutramine, a controlled substance and prescription weight-loss drug, which was the subject of a recent study whose preliminary findings showed an association between sibutramine use and increased risk of heart attack and stroke in patients who have a history of heart disease; and ephedrine, a stimulant drug that is legally marketed over-the-counter for temporary relief of asthma but can pose a risk to people with certain cardiovascular conditions.
These active pharmaceutical ingredients also may interact with other medications and result in a serious adverse event.
Consumers and healthcare professionals are encouraged to report adverse events related to the use of Que She to the FDA’s MedWatch Safety Information and Adverse Event Reporting Program: online at FDA.gov/MedWatch/report.htm; by phone at (800) FDA-1088, or (800) 332-1088; or, by returning FDA form 3500, available on the MedWatch “Download Forms” page by mail to the address on the pre-addressed form or by fax at (800) FDA-0178.